<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230212057396N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-11-25</date_registration>
      <primary_sponsor>Neurology Research Center</primary_sponsor>
      <public_title>The Effectiveness of Mindfulness Integrated Cognitive behavioral Therapy (MiCBT) on the Negative Emotions, improvement of executive function, Emotion Regulation  and change of quantitative electroencephalography waves (QEEG) of patients with Multiple Sclerosis</public_title>
      <acronym></acronym>
      <scientific_title>The Effectiveness of Mindfulness Integrated Cognitive behavioral Therapy (MiCBT) on the Negative Emotions, improvement of executive function, Emotion Regulation  and change of quantitative electroencephalography waves (QEEG) of patients with Multiple Sclerosis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-12-31</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>52</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68551</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: The present research is a semi-experimental design with pre-test and post-test with the control group, Randomization description: After reviewing and confirming the criteria for entering and exiting the study, MS patients will be placed in two intervention and control groups of 26 people, so that the names of 26 people who are selected in the lottery will be placed in the intervention group and The rest will be in the control group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Multiple sclerosis. Condition 2: Negative Emotional States. Condition 3: Executive Functions. Condition 4: Quantitative Electroencephalographic Waves. Condition 5: Emotion Regulation.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: For the participants of this group, 8 sessions of Mindfulness Integrated Cognitive behavioral Therapy MiCBT, will be implemented within the framework of the Brauno Cayoun protocol. Intervention 2: Control group: At the time of conducting the research, the control group will not receive any intervention. The goal is to check whether the passage of time creates a change in these patients or not, but after the completion of the research, the participants of the control group will also receive 8 sessions of MiCBT intervention as an appreciation for conducting the research. will be executed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
the data are collected anonymously

When:
in case of request the data are available anonymous

To whom:
Other researchers have research plans from reputable centers

Conditions:
researchers with credible studies from reputable constitutions

Where to obtain:
After publication of the article to the corresponding author

How to obtain:
contact with the corresponding author

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Atefeh Fakhrmand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alzahra University, North Sheikh Bahaee St., Deh-e Vanak, Tehran, I. R. of Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۹۹۳۸۹۳۹۷۳</zip>
        <telephone>+98 21 8805 8925</telephone>
        <email>A.Fakhrmand@Alzahra.ac.ir</email>
        <affiliation>The University of Alzahra Tehran</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hoda Kamali</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kerman University of Medical Sciences, Medical University Campus,     Haft-Bagh Highway, Kerman, Iran</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616913555</zip>
        <telephone>+98 34 3132 5856</telephone>
        <email>Hoda_3303@Yahoo.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The criteria for entering the study are all MS patients with an official diagnosis of MS
There are men and women with an age range of 20-50 years.
They have at least a diploma.
The right is superior.
They take beta interferon medicine.
All patients completed an informed consent form.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Conditions for not entering the study:MS patients suffer from other psychiatric and neurological disorders.
MS patients consumed alcohol or drugs at least two weeks before the study.
MS patients received psychological treatment near the study
MS patients have epilepsy.
They have a history of seizures, brain trauma and other structural brain diseases.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G35</hc_code>
      <hc_code>R45</hc_code>
      <hc_code></hc_code>
      <hc_code>R94.0</hc_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Multiple sclerosis</hc_keyword>
      <hc_keyword>Symptoms and signs involving emotional state</hc_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword>Abnormal results of function studies of central nervous system</hc_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Behavior</i_code>
      <i_code>Behavior</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: For the participants of this group, 8 sessions of Mindfulness Integrated Cognitive behavioral Therapy MiCBT, will be implemented within the framework of the Brauno Cayoun protocol.</i_keyword>
      <i_keyword>Control group: At the time of conducting the research, the control group will not receive any intervention. The goal is to check whether the passage of time creates a change in these patients or not, but after the completion of the research, the participants of the control group will also receive 8 sessions of MiCBT intervention as an appreciation for conducting the research. will be executed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Negative Emotional States. Timepoint: Emotional states will be measured once before the implementation of the intervention in the first session (pre-test) and once in the last session after the intervention. Method of measurement: In order to examine emotional states, the original version of DASS has 42 questions, but later it was shortened and reduced to 21 questions. This questionnaire has 21 items including 8 items related to depression (D), 7 items related to anxiety (A) and 6 items related to stress (S).</prim_outcome>
      <prim_outcome>Executive Functions. Timepoint: Executive functions will be measured once before the implementation of the intervention in the first session (pre-test) and once in the last session after the intervention. Method of measurement: EFQ standard questionnaire of executive functions is used to check executive functions. This questionnaire was compiled by Tos Nejati (2012) and has 30 items and seven subscales. The scoring method is a 5-point Likert scale from almost never (5) to always (1). Its seven subscales include memory (1 to 6), selective attention, questions 7 to 12), decision making (questions 13 to 17), planning (questions 18 to 20), persistent memory (questions 21 to 23), social cognition. (questions 24 to 26) and cognitive flexibility (questions 27 to 30).</prim_outcome>
      <prim_outcome>Quantitative electroencephalographic waves(QEEG). Timepoint: QEEG will be measured once before the implementation of the intervention in the first session (pre-test) and once in the last session after the intervention. Method of measurement: An EEG device made in Iran under a Canadian license will be used to record the electroencephalogram. In this method, signals and brain waves are recorded by the electrodes on the scalp. This information is entered into the computer and converted into numbers and graphs through QEEG (quantitative brain mapping).</prim_outcome>
      <prim_outcome>Emotion Regulation. Timepoint: Cognitive emotional regulation will be measured once before the implementation of the intervention in the first session (pre-test) and once in the last session after the intervention. Method of measurement: CERQ cognitive regulation of emotion questionnaire is used to examine the cognitive regulation of emotion. It is a self-assessment questionnaire designed by Garnevsky and Kraich. This questionnaire has 36 questions that have 9 subscales.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Neurology Research Center</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-10-30</approval_date>
        <contact_name>Kerman University of Medical Sciences, Iran</contact_name>
        <contact_address>Kerman University of Medical Sciences, Medical University Campus,     Haft-Bagh Highway, Kerman, Iran Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
